- Home
- NFJ vs TNDM Comparison
NFJ vs TNDM Comparison
Compare NFJ & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFJ
- TNDM
- Stock Information
- Founded
- NFJ 2005
- TNDM 2006
- Country
- NFJ United States
- TNDM United States
- Employees
- NFJ N/A
- TNDM N/A
- Industry
- NFJ Finance: Consumer Services
- TNDM Medical/Dental Instruments
- Sector
- NFJ Finance
- TNDM Health Care
- Exchange
- NFJ Nasdaq
- TNDM Nasdaq
- Market Cap
- NFJ 1.2B
- TNDM 1.1B
- IPO Year
- NFJ N/A
- TNDM 2013
- Fundamental
- Price
- NFJ $12.82
- TNDM $14.59
- Analyst Decision
- NFJ
- TNDM Buy
- Analyst Count
- NFJ 0
- TNDM 17
- Target Price
- NFJ N/A
- TNDM $22.76
- AVG Volume (30 Days)
- NFJ 223.5K
- TNDM 1.8M
- Earning Date
- NFJ 01-01-0001
- TNDM 11-06-2025
- Dividend Yield
- NFJ 9.01%
- TNDM N/A
- EPS Growth
- NFJ N/A
- TNDM N/A
- EPS
- NFJ N/A
- TNDM N/A
- Revenue
- NFJ N/A
- TNDM $1,001,719,000.00
- Revenue This Year
- NFJ N/A
- TNDM $8.27
- Revenue Next Year
- NFJ N/A
- TNDM $9.63
- P/E Ratio
- NFJ N/A
- TNDM N/A
- Revenue Growth
- NFJ N/A
- TNDM 25.84
- 52 Week Low
- NFJ $10.45
- TNDM $9.98
- 52 Week High
- NFJ $12.86
- TNDM $38.28
- Technical
- Relative Strength Index (RSI)
- NFJ 42.18
- TNDM 58.26
- Support Level
- NFJ $12.81
- TNDM $14.73
- Resistance Level
- NFJ $13.04
- TNDM $15.51
- Average True Range (ATR)
- NFJ 0.16
- TNDM 0.67
- MACD
- NFJ -0.02
- TNDM -0.04
- Stochastic Oscillator
- NFJ 8.33
- TNDM 67.56
About NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. The fund pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.